Cancer, Hematology, Post-cancer
Conditions
Keywords
post-cancer, sarcopenia, medical evaluation, muscle
Brief summary
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital). JUMP research is part of axis 2 of the 2021-2030 cancer plan: Limiting sequelae and improving quality of life, through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. This non-interventional research is classified as research involving human subjects, class 3 . The objective of this research is to evaluate the impact of cancer on the musculoskeletal system and to test ultrasound as a clinical examination for the detection of sarcopenia in this population.
Interventions
OTHERJUMP group
patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Age : 18 to 74 years * localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy * patient who benefited from the post-cancer assessment day
Exclusion criteria
* Active cancer (relapse or new cancer) * Pregnant or breastfeeding women * Major cognitive impairment making comprehension and exercise difficult * Amputation of both lower limbs (for ultrasound) * Difficulty understanding oral and written French * Adults under legal protection (guardianship, curatorship or safeguard of justice)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analyze the correlation between muscle mass (thickness) of the quadriceps (rectus femoris) assessed in axial sections by ultrasound and the reference muscle mass index (Appendicular Lean Mass (ALM)/height²) assessed by DEXA | through study completion, an average of 9 years | Analyze the correlation between muscle mass (thickness) of the quadriceps (rectus femoris) assessed in axial sections by ultrasound and the reference muscle mass index (Appendicular Lean Mass (ALM)/height²) assessed by DEXA Mean thickness of the quadriceps (straight femoris) measured by ultrasound compared to the Appendicular Lean Mass/size² in DEXA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between ultrasound muscle indices and muscle functional tests | through study completion, an average of 9 years | Calculation of Functional Indices and questionnaire scores: grip strength, TM6, 30-second sit-to-stand test, SARC-F and IPAQ |
| Correlation between muscle biological markers (irisin, myostatin, FGF19, TGFb, decarboxylated osteocalcin, microRNA) and the diagnosis of sarcopenia (according to EWSGOP 2019 and BAUMGARTNER) | through study completion, an average of 9 years | Serum biomarker assays: myostatin, irisin, micro-RNA, osteocalcin, FGF19 and diagnosis of sarcopenia assessed according to Baumgartner and to to EWSGOP 2019 definitions |
| Correlation between the ultrasound muscle indexes and the scannographic index of the paravertebral muscles (SMI L3, T12 and T7, studied by IA) | through study completion, an average of 9 years | Evaluation of the section surface of the rectus femoris in ultrasound, of the adipose infiltration index of the rectus femoris on ultrasound and of the Skeletal Muscle Index (SMI) L3, T12 and T7 in CT (gold standard) |
| Reproducibility of muscle ultrasound, in a subgroup of patients, inter-observer (n=10 patients) | through study completion, an average of 9 years | ICC of the thickness of the quadriceps, of its cross-sectional area interobserver (subpopulation of 10 patients) |
| Reproducibility of muscle ultrasound, in a subgroup of patients, intra-observer (n=10 patients). | through study completion, an average of 9 years | ICC of the thickness of the quadriceps, its cross-sectional area intraobserver (subpopulation of 10 patients) |
| Correlation between muscle biological markers (irisin, myostatin, FGF19, TGFb, decarboxylated osteocalcin, microRNA) and ultrasound, densitometric, scannographic and functional parameters | through study completion, an average of 9 years | Serum biomarker assays: myostatin, irisin, micro-RNA, osteocalcin, FGF19, interpretation of images (ultrasound, densitometry, scanner) and results of functional tests |
Countries
France
Contacts
Primary ContactCyrille CONFAVREUX, Md,PhD
Outcome results
None listed